Amgen Inc. (NASDAQ:AMGN) Shares Sold by Schmidt P J Investment Management Inc.

Schmidt P J Investment Management Inc. lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,793 shares of the medical research company’s stock after selling 83 shares during the quarter. Schmidt P J Investment Management Inc.’s holdings in Amgen were worth $728,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. Capital Performance Advisors LLP acquired a new stake in shares of Amgen in the third quarter valued at about $25,000. Legacy Investment Solutions LLC acquired a new stake in Amgen in the 3rd quarter worth about $29,000. Matrix Trust Co acquired a new position in shares of Amgen during the third quarter valued at approximately $36,000. Heck Capital Advisors LLC purchased a new position in shares of Amgen in the fourth quarter valued at approximately $36,000. Finally, Livelsberger Financial Advisory acquired a new stake in shares of Amgen in the third quarter worth approximately $56,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AMGN. Wells Fargo & Company decreased their price objective on Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a report on Friday, January 10th. Redburn Partners decreased their price target on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Citigroup dropped their price objective on shares of Amgen from $310.00 to $295.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Leerink Partners lowered their target price on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Finally, TD Cowen increased their price target on Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a report on Monday, October 21st. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and a consensus target price of $314.00.

Amgen Stock Up 6.5 %

NASDAQ:AMGN opened at $307.81 on Thursday. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The stock’s fifty day moving average is $271.14 and its two-hundred day moving average is $303.52. The stock has a market capitalization of $165.46 billion, a price-to-earnings ratio of 39.41, a price-to-earnings-growth ratio of 2.87 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 168.35% and a net margin of 13.00%. Research analysts anticipate that Amgen Inc. will post 19.56 EPS for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.09%. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is 115.24%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.